Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Study of the Efficacy and Safety of 5 and 10mg VESIcare® (Solifenacin Succinate) in Patients With Overactive Bladder Symptoms VOLT: VESIcare® Open-Label Trial

NCT00463541 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00463541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00463541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Study of the Efficacy and Safety of 5 and 10mg VESIcare® (Solifenacin Succinate) in Patients With Overactive Bladder Symptoms VOLT: VESIcare® Open-Label Trial
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2004
Completion date
April 30, 2005
Enrollment
2,225 (actual)
Sites
198

Conditions

As the registry lists them; a condition with its own page is linked.

urinary bladder, overactive